Literature DB >> 33228417

The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.

Qurat Ul Ain Riaz Sipra1, Rachna Shroff2.   

Abstract

Entities:  

Keywords:  Cholangiocarcinoma; biliary tract cancer; extrahepatic cholangiocarcinoma; fibroblast growth factor receptor; genetics; genomic profiling; intrahepatic cholangiocarcinoma; isocitrate dehydrogenase; targeted therapies

Mesh：

Substances：

Year:  2020        PMID： 33228417     DOI： 10.1080/13543784.2021.1849139

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


× No keyword cloud information.
  3 in total

1.  IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.

Authors:  Stephen P Hack; Wendy Verret; Sohail Mulla; Bo Liu; Yulei Wang; Teresa Macarulla; Zhenggang Ren; Anthony B El-Khoueiry; Andrew X Zhu
Journal:  Ther Adv Med Oncol       Date:  2021-07-31       Impact factor: 8.168

2.  Novel Targeted Therapies for Advanced Cholangiocarcinoma.

Authors:  Alessandro Rizzo; Giovanni Brandi
Journal:  Medicina (Kaunas)       Date:  2021-02-26       Impact factor: 2.430

Review 3.  Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.

Authors:  Alessandro Rizzo
Journal:  Medicina (Kaunas)       Date:  2021-05-08       Impact factor: 2.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.